Physician profile
Lester Pan
NPI 1598790826
$25,277.02
in general payments reported to CMS, 2019-2025
50 companies · $2,858 in 2025
The $2,858 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,925 · 2020: $3,584 · 2021: $5,225 · 2022: $4,260 · 2023: $3,843 · 2024: $2,583 · 2025: $2,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,777 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $375 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,777.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $375.00 |
| Education | $131.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,221.70 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $2,742.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,984.85 | 2019-2025 | |
| Novo Nordisk INC | $1,736.80 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,649.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Nestle Healthcare Nutrition INC. | $1,380.56 | 2020-2023 | |
| Lilly USA, LLC | $1,330.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,203.86 | 2019-2025 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $1,013.80 | 2020-2025 | Livalo, Seglentis, Zoryve |
| Gilead Sciences, INC. | $837.37 | 2019-2025 | |
| Astellas Pharma US INC | $779.92 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $740.74 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $574.60 | 2024-2025 | Zenpep |
| Radius Health, INC. | $557.02 | 2019-2022 | |
| Amgen INC. | $528.10 | 2019-2025 | Otezla, Repatha, Otezla |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.